FORA Capital’s Apellis Pharmaceuticals APLS Stock Holding History

FORA Capital’s Portfolio APLS Stock Details APLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-7,572	Closed	-$305K	–	364
2026 Q1	$305K	Buy	+7,572	New	+$163K	0.02%	364
2024 Q4	–	Sell	-14,623	Closed	-$422K	–	388
2024 Q3	$422K	Buy	+14,623	New	+$542K	0.05%	318
2023 Q3	–	Sell	-31,203	Closed	-$2.84M	–	450
2023 Q2	$2.84M	Buy	31,203 +23,292	+294%	+$2.01M	0.4%	70
2023 Q1	$522K	Buy	+7,911	New	+$456K	0.05%	346
2022 Q2	–	Sell	-14,009	Closed	-$693K	–	422
2022 Q1	$693K	Buy	+14,009	New	+$618K	0.12%	223
2021 Q2	–	Sell	-1,378	Closed	-$59K	–	864
2021 Q1	$59K	Buy	+1,378	New	+$65.2K	0.02%	517
2020 Q1	–	Sell	-2,156	Closed	-$66K	–	1024
2019 Q4	$66K	Buy	+2,156	New	+$59.7K	0.01%	847

Other funds holding APLS

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

FORA Capital's APLS Position: Q2 2026 in Review

FORA Capital sold out of Apellis Pharmaceuticals (APLS) in Q2 2026, closing a stake of 7,572 shares — an estimated $305K sold.

FORA Capital first reported a position in APLS in Q4 2019 and held it in 7 quarters. The position peaked at $2.84M in Q2 2023. 1 fund tracked by Wall St. Rank holds APLS as of Q2 2026.

FORA Capital reported no remaining Apellis Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
FORA Capital sold 7,572 Apellis Pharmaceuticals shares in Q2 2026, an estimated $305K.
FORA Capital first reported a position in Apellis Pharmaceuticals in Q4 2019 and held it in 7 quarters.
FORA Capital's Apellis Pharmaceuticals position peaked at $2.84M in Q2 2023.
1 fund tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q2 2026.

Based on FORA Capital's 13F filing for Q2 2026, filed 13 Aug 2026.